Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of LCTX is 4.3 and suggests 156% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell